Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
29 employees
Xcell Biosciences, a biotech firm, innovates vitro tech for capturing and analyzing cancer cells from patient samples.
HQ
Founded
2012
Xcell Biosciences, founded with a mission to revolutionize cancer treatment, focuses on developing advanced in vitro technologies for capturing, growing, and analyzing cancer cells directly from patient blood samples. The company's core vision is to enhance the effectiveness of cell therapies by creating scalable platforms that mimic tumor microenvironments. Their primary product, the Avatar Foundry, is designed to improve the metabolic fitness, transduction, expansion, and potency of cell therapies, making them more effective in clinical applications.
Notable figures associated with Xcell Biosciences include leading experts in biotechnology and oncology. The company has attracted significant investment from prominent venture capital firms dedicated to advancing medical technology. Key achievements include the successful development and implementation of their scalable cell therapy manufacturing platform, which has shown promising results in enhancing the efficacy of cancer treatments. Xcell Biosciences' innovative approach has made a substantial impact on the field of personalized medicine, offering new hope for patients through more effective and tailored cancer therapies.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Cell Therapies
Technology
Biotech
Tags
Biotech
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Xcell Biosciences founded?
Xcell Biosciences was founded in 2012.
Where is Xcell Biosciences's headquarters located?
Xcell Biosciences's headquarters is located in San Francisco, CA, US.
When was Xcell Biosciences's last funding round?
Xcell Biosciences's most recent funding round was for $27.5M (USD) in January 2022.
How many employees does Xcell Biosciences have?
Xcell Biosciences has 29 employees as of Feb 5, 2024.
How much has Xcell Biosciences raised to-date?
As of July 05, 2023, Xcell Biosciences has raised a total of $39.6M (USD) since Jan 19, 2022.
Add Comparison
Total Raised to Date
$39.6M
USD
Last Update Jan 19, 2022
Last Deal Details
$27.5M
USD
Jan 19, 2022
Series B
Current Employees
29
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts